Eiken Chemical Co., Ltd. · TSE:4549
Eiken Chemical — Q2 FY2012 Earnings Presentation
14 slides from Eiken Chemical's earnings presentation, Oct 27, 2011
Slide 1: Business performance briefing for the second quarter ending Mar. 2012
The business performance briefing for the second quarter ending Mar. 2012 (Apr. 1, 2011 to Sep, 30, 2011) EIKEN CHEMICAL CO., LTD. Oct. 27, 2011 EIKEN CHEMICAL CO., LTD. 1 Consolidated operating results for the second quarter ending Mar. 2012 EIKEN CHEMICAL CO., LTD EIKEN CHEMICAL CO., LTD. 2 1
Slide 2: Overview of consolidated performance for the second quarter
Overview of consolidated performance for the second quarter ending Mar. 2012 (Millions of yen) First half of the term ending Mar. 2012 Difference from target value YoY change Target value Actual results Ratio Difference Results Difference Net sales 14,290 14,121 100.0 -169 14,010 +111 Operating inco
Slide 3: Consolidated sales for product category
Consolidated sales for product category (Millions of yen) Term ended Mar. 2010 Term ended Mar. 2011 First half of the term Immunological and 1st half Full year 1st half Full year ending Mar. 2012 serological reagents 4,419 8,626 4,532 8,909 4,588 First half ●1.2% increase from the 8,909 correspondin
Slide 4: Consolidated sales for product category
Consolidated sales for product category (Millions of yen) Term ended Mar. 2010 Term ended Mar. 2011 First half of the term 1st half Full year 1st half Full year ending Mar. 2012 Dry chemistry reagents 981 1,873 1,001 1,948 1,001 First Half ● The sales of “Uropaper α,” 1,948 specialized reagents for
Slide 5: Consolidated sales for product category
Consolidated sales for product category (Millions of yen) Term ended Mar. 2010 Term ended Mar. 2011 Industry products (Culture First half of the term 1st half Full year 1st half Full year ending Mar. 2012 media for equipment, food and environment category) 1,321 2,552 1,236 2,441 1,195 First half ●
Slide 6: Overseas sales
Overseas sales (Millions of yen) Term ended Mar. 2010 Term ended Mar. 2011 First half of the term 1st half Full year 1st half Full year ending Mar. 2012 Overseas Sales 709 1,632 686 1,689 786 Sales Sales by product category First half Fecal occult blood diagnostic reagents Other ● 14.5% increase fro
Slide 7: Balance sheets; R&D cost and investment in equipment
Balance sheets First half of term ending (Millions of yen) Mar. 2012 Term ended Mar. 2011 Main reasons of increase/decrease Current liabilities Current liabilities ●Current assets 9,782（+377） - Cash and deposits (744) 9,405 Current assets - Notes and account receivable 626 20,225 Noncurrent Current
Slide 8: Primary strategies for the second quarter ending Mar. 2012
Primary strategies for the second quarter ending Mar. 2012 EIKEN CHEMICAL CO., LTD Primary strategies for the second quarter ending Mar. 2012 1. Promotion of the sale measure Japan ・ Strengthening of sales promotion system for our flagship products ・ Sales promotion of LAMP reagent for tuberculosis
Slide 9: Primary strategies: sales promotion, R&D and new products
Primary strategies for the second quarter ending Mar. 2012 1. Promotion of the sale measure Europe ・ Research activity of the OC Screening bid in France Screening start : 2013 ・ Adoption decision of the OC screening in Slovenia ・ Establishment of Europe office (Amsterdam) Asia, etc ・ Adoption decisi
Slide 10: FIND business; Return to shareholders (Interim dividend)
Primary strategies for the second quarter ending Mar. 2012 3. FIND business (1) Tuberculosis test [Outside Japan] Demonstration Study started in Peru, Uganda and India (phase I) (2) Malaria Evaluation Study started (3) HAT (Human African Typanosomiasis) Launch of research reagents for FIND, July, 20
Slide 11: Primary strategies for the term ending Mar. 2012
Primary strategies and earnings forecast for the term ending Mar. 2012 (the 74th term) EIKEN CHEMICAL CO., LTD Primary strategies for the term ending Mar. 2012 (the 74th term) 1. Sales promotion (1) Domestic market ・Sales promotion of LAMP reagents and equipment Respiratory infectious disease (tuber
Slide 12: Primary strategies: FIND business and productivity improvement
Primary strategies for the term ending Mar. 2012 (the 74th term) 2. FIND business (1) Tuberculosis test [Overseas] ・Demonstration Study to be started phase II ・2012 Second half Strategic And Technical Advisory Group For Tuberculosis Meeting * Application procedures to obtain recommendation from WHO
Slide 13: Consolidated earnings forecast for the 74th term
Consolidated earnings forecast for the term ending Mar. 2012 (the 74th term) Target value (Millions of yen) Consolidated Non-consolidated Amount Ratio [%] YoY change [%] Amount Ratio [%] YoY change [%] Net sales 27,610 100.0 100.2 27,580 100.0 100.1 Operating income 2,210 8.0 81.6 2,210 8.0 81.0 Ord
Slide 14: Notes
Notes This document is not the disclosed reference for financial instruments and exchange. Its accuracy and integrity are not guaranteed. The estimates, etc. written in this document are based on currently available information, and so actual values may be different due to various factors. This docu